ReviewClinical & translational immunology2017
Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?
Review in Clinical & translational immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- Unraveling vascular mechanisms in melanoma: roles of angiogenesis and vasculogenic mimicry in tumor progression and therapeutic resistance.Cancer biology & medicine · 2025Review
- Inhibitor of DNA binding-1 is a key regulator of cancer cell vasculogenic mimicry.Molecular oncology · 2025Article
- Apelin/APJ: Another Player in the Cancer Biology Network.International journal of molecular sciences · 2025Review
- Innate Immune Cells in Melanoma: Implications for Immunotherapy.International journal of molecular sciences · 2024Review
- Single-cell adhesive profiling in an optofluidic device elucidates CD8Cell reports methods · 2024Article
- A Fucose-Containing Sulfated Polysaccharide from Spatoglossum schröederi Potentially Targets Tumor Growth Rather Than Cytotoxicity: Distinguishing Action on Human Melanoma Cell Lines.Marine biotechnology (New York, N.Y.) · 2024Article
- Vasculogenic mimicry structures in melanoma support the recruitment of monocytes.Oncoimmunology · 2022Article
- Endothelial cell-derived Apelin inhibits tumor growth by altering immune cell localization.Scientific reports · 2021Article
- Evolution of delayed resistance to immunotherapy in a melanoma responder.Nature medicine · 2021Article
- Green Propolis Compounds (Baccarin and p-Coumaric Acid) Show Beneficial Effects in Mice for Melanoma Induced by B16f10.Medicines (Basel, Switzerland) · 2021Article
- Identification of Four Genes as Prognosis Signatures in Lung Adenocarcinoma Microenvironment.Pharmacogenomics and personalized medicine · 2021Article
- Nanotechnology Promotes Genetic and Functional Modifications of Therapeutic T Cells Against Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Review
- Effects of anti-PD-1 immunotherapy on tumor regression: insights from a patient-derived xenograft model.Scientific reports · 2020Article
- Review
- Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.Nature reviews. Drug discovery · 2019Review
- Transcriptome-derived stromal and immune scores infer clinical outcomes of patients with cancer.Oncology letters · 2018Article
- Overexpression of adhesion molecules and barrier molecules is associated with differential infiltration of immune cells in non-small cell lung cancer.Scientific reports · 2018Article
- A Computational Approach Identifies Immunogenic Features of Prognosis in Human Cancers.Frontiers in immunology · 2018Article
- Molecular Magnetic Resonance Imaging of Endothelial Activation in the Central Nervous System.Theranostics · 2018Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastatic melanoma remains a fatal disease to many worldwide, even after the breakthrough introduction of targeted therapies such as BRAF inhibitors and immune checkpoint blockade therapies such as CTLA-4 and PD-1 inhibitors. With advances in our understanding of this disease, as well as the increasing data gathered from patient studies, the significance of the host immune response to cancer progression and response to treatment is becoming clear. More specifically, the presence of intratumoral CD8
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.